Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) have earned an average recommendation of “Buy” from the twenty-one research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $72.86.

RARE has been the topic of several research reports. Canaccord Genuity set a $80.00 target price on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, December 5th. Barclays raised their target price on Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 5th. Evercore ISI upgraded Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating in a research report on Monday, January 22nd. Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Finally, BidaskClub downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th.

Ultragenyx Pharmaceutical (RARE) traded down $2.08 during midday trading on Friday, hitting $51.27. The stock had a trading volume of 801,763 shares, compared to its average volume of 693,617. The stock has a market capitalization of $2,578.08, a P/E ratio of -7.43 and a beta of 1.83. Ultragenyx Pharmaceutical has a 1-year low of $43.14 and a 1-year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, meeting the consensus estimate of ($1.87). The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.02 million. Ultragenyx Pharmaceutical had a negative return on equity of 79.94% and a negative net margin of 40,013.64%. The business’s quarterly revenue was up 81.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.64) earnings per share. research analysts forecast that Ultragenyx Pharmaceutical will post -7.31 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of RARE. SG Americas Securities LLC acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth $156,000. Kazazian Asset Management LLC acquired a new stake in Ultragenyx Pharmaceutical during the second quarter worth $213,000. Fox Run Management L.L.C. acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth $213,000. Ameritas Investment Partners Inc. increased its stake in Ultragenyx Pharmaceutical by 7.7% during the second quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 248 shares during the last quarter. Finally, Amalgamated Bank increased its stake in Ultragenyx Pharmaceutical by 7.6% during the second quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock worth $309,000 after acquiring an additional 352 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/brokerages-set-ultragenyx-pharmaceutical-inc-rare-pt-at-72-86/1837705.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.